Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing ...

Activation of the α7 nicotinic acetylcholine receptor may be therapeutically useful against acute lung injury by suppressing expression of pro-inflammatory genes.

Cash runway into Q3 2026 AFFIRM-1 Phase 3 clinical trial of BNC-210 in social anxiety disorder on track for topline readout in Q3 2025 α7 nicotinic acetylcholine receptor PAM MK-1167 partnered with ...

Initiation by Merck of a Phase 2 trial in Alzheimer’s disease with partnered α7 nicotinic acetylcholine receptor PAM MK-1167 highlights company’s pipeline diversification beyond BNC210 US $15M ...

Initiation by Merck of a Phase 2 trial in Alzheimer’s disease with partnered α7 nicotinic acetylcholine receptor PAM MK-1167 highlights company’s pipeline diversification beyond BNC210 US $ ...

President and CEO of Neuphoria, Spyros Papapetropoulos, M.D., Ph.D., expressed enthusiasm over the progress, indicating that the milestone underscores the potential of α7 nicotinic acetylcholine ...

Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social ...

More information: Spyridon Papapetropoulos et al, BNC210, an α7 Nicotinic Receptor Modulator, in Post-Traumatic Stress Disorder, NEJM Evidence (2024). DOI: 10.1056/EVIDoa2400380 Journal ...

In a modified intent-to-treat analysis of 182 patients, treatment effects with BNC210 -- a novel α7 nicotinic acetylcholine receptor-negative allosteric modulator -- were seen as early as week 4 ...

today announced an update on the company’s α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) collaboration with MSD (known as Merck & Co., Inc., Rahway NJ ...

Three days after appointing its next CEO, Bionomics had to break the news to investors that its lead asset has flunked a phase 2 trial in acute social anxiety disorder (SAD). The candidate, dubbed ...